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ABSTRACT Whooping cough is a highly contagious respiratory disease caused by
Bordetella pertussis. Despite widespread vaccination, its incidence has been rising
alarmingly, and yet, the physiology of B. pertussis remains poorly understood. We
combined genome-scale metabolic reconstruction, a novel optimization algorithm,
and experimental data to probe the full metabolic potential of this pathogen, using
B. pertussis strain Tohama I as a reference. Experimental validation showed that B.
pertussis secretes a significant proportion of nitrogen as arginine and purine nucleo-
sides, which may contribute to modulation of the host response. We also found that
B. pertussis can be unexpectedly versatile, being able to metabolize many com-
pounds while displaying minimal nutrient requirements. It can grow without cys-
teine, using inorganic sulfur sources, such as thiosulfate, and it can grow on organic
acids, such as citrate or lactate, as sole carbon sources, providing in vivo demonstra-
tion that its tricarboxylic acid (TCA) cycle is functional. Although the metabolic re-
construction of eight additional strains indicates that the structural genes underlying
this metabolic flexibility are widespread, experimental validation suggests a role of
strain-specific regulatory mechanisms in shaping metabolic capabilities. Among five
alternative strains tested, three strains were shown to grow on substrate combina-
tions requiring a functional TCA cycle, but only one strain could use thiosulfate. Fi-
nally, the metabolic model was used to rationally design growth media with 2-fold
improvements in pertussis toxin production. This study thus provides novel insights
into B. pertussis physiology and highlights the potential, but also the limitations, of
models based solely on metabolic gene content.
IMPORTANCE The metabolic capabilities of Bordetella pertussis, the causative agent
of whooping cough, were investigated from a systems-level perspective. We con-
structed a comprehensive genome-scale metabolic model for B. pertussis and chal-
lenged its predictions experimentally. This systems approach shed light on new po-
tential host-microbe interactions and allowed us to rationally design novel growth
media with 2-fold improvements in pertussis toxin production. Most importantly,
we also uncovered the potential for metabolic flexibility of B. pertussis (significantly
larger range of substrates than previously alleged; novel active pathways allowing
growth in minimal, nearly mineral nutrient combinations where only the carbon source
must be organic), although our results also highlight the importance of strain-specific
regulatory determinants in shaping metabolic capabilities. Deciphering the underly-
ing regulatory mechanisms appears to be crucial for a comprehensive understanding
of B. pertussis’s lifestyle and the epidemiology of whooping cough. The contribution
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of metabolic models in this context will require the extension of the genome-scale
metabolic model to integrate this regulatory dimension.
KEYWORDS Bordetella pertussis, whooping cough, vaccine production, genome-scale
metabolic model, rational medium design, constraint-based modeling
Pertussis, or whooping cough, is a highly contagious respiratory disease caused bythe Gram-negative bacterium Bordetella pertussis. Despite widespread vaccination,
it remains an important health burden, with an estimated 16 million cases in 2008 (1).
As recently as 2013, it was still responsible for 1% of the global mortality (60,000 deaths)
in children under 5 years. Moreover, from the main causes of death for this demo-
graphic, it is the one with the lowest reduction between 2000 and 2013 (0.2%) (2);
rather, the number of reported cases has increased during the last 2 decades. This not
only urges for improved strategies to fight the disease, but it also questions our
understanding of B. pertussis physiology.
Metabolic capabilities play a key role in defining allowable environmental niches of
pathogens and therefore contribute to an understanding of the epidemiology of
diseases. Metabolites also participate in host-pathogen interactions (3) and can provide
new targets for therapeutic approaches. Yet, the understanding of the metabolism of
B. pertussis has remained virtually unchanged since the 1960s, with only few recent
studies dealing with this aspect of its physiology (for instance references 4 and 5). B.
pertussis is described as fastidious in its nutritional requirements and is unable to
survive outside the human host (6, 7). Today, it is still merely viewed as being unable
to ferment sugars (8), is auxotrophic to niacin (9), and it strictly relies on amino acids
as sources of energy, carbon, and nitrogen and on cysteine as a sulfur source (8).
However, numerous discrepancies are found between the genome sequence informa-
tion and the observed phenotypes, as well as between reports from different research
groups. Some of the issues that we will study and resolve in this work, are (i) whether
the tricarboxylic acid (TCA) cycle is fully functional (4, 5, 10), (ii) whether organic sulfur
sources (cysteine) are mandatory for growth (11), and (iii) what are the missing
nitrogen-containing end products of B. pertussis when growing in vitro on glutamate
(several studies indicate a gap of up to 40% in the N balance [12, 13]).
Genome-scale models are inventories of the metabolic capabilities encoded in a
genome. In recent years, powerful computational tools have been developed that allow
the reconstruction of metabolic pathways for any organism (14, 15). These tools require
genome information, basic cell physiology and biochemical knowledge, and some
experimental data on cell growth. The reconstructed metabolic networks can subse-
quently be interrogated to define growth substrates and metabolic end products, as
well as to identify links between parts of the metabolism that remain elusive to
intuition (15).
In the present work, we used these techniques to reinvestigate the metabolism of
B. pertussis from a systems-level perspective. In a first step, we developed a compre-
hensive genome-scale metabolic network for B. pertussis in an effort to reconcile
physiological observations with genomic information. A detailed biomass reaction was
formulated based on experimental data, and new pathways were introduced to ac-
commodate the synthesis of biomass components. We further developed a novel
algorithm that enumerates all possible minimal nutrient combinations that support the
formation of this highly specific biomass. In this way, we could systematically probe the
full metabolic capabilities of B. pertussis.
Through model-guided experimentation, we discovered that B. pertussis can be
much more versatile than previously reported and is able to grow on very minimal
media, where only the carbon source must be organic, although such behaviors are
strain dependent. Our model also predicted the excretion of novel nitrogen-containing
products that may shed new light on potential host-pathogen interactions. Finally, we
used the validated model to rationally engineer new medium formulations for the
production of vaccine antigens. Improved media resulted in up to 2.4-fold increased
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pertussis toxin production. Our work demonstrates the innovation potential of com-
prehensive in silico approaches but also highlights their limitations.
RESULTS
Metabolic network of B. pertussis Tohama I. The metabolic network of B. pertussis
Tohama I was reconstructed based on its genome sequence (16) using standard
methods that rely on available genome-scale metabolic models (14, 17). Due to
phylogenetic proximity, model iAF1260 for Escherichia coli MG1655 was used as the
template (18) to generate an automated draft metabolic network for Tohama I. The
draft network was extensively curated based on the literature and experimental data
obtained in the present study. We started with a thorough experimental characteriza-
tion of exometabolite fluxes (Fig. S1 and Data Set S1 in the supplemental material) and
biomass composition (Data Set S2) at different growth stages, using reference batch
fermentations in a chemically defined medium derived from the Stainer-Scholte me-
dium (MSS-CDM). These data were used to calibrate and refine the model through
iterative cycles of in silico simulations and experimentation. The final model was named
iBP1870 (Fig. 1); it contains exchange reactions for 202 compounds defining the
potential for uptake and excretion of compounds and 1,473 internal reactions, of which
1,017 are gene associated, representing 762 genes (22% of the genome) (Table S1).
Important features of the model include a detailed B. pertussis-specific biomass
equation (Fig. S2) and many reactions not defined yet in the E. coli model, such as in
pathways of amino acid metabolism, iron acquisition, sulfur metabolism, and biosyn-
thesis of lipooligosaccharides and storage compounds (Data Set S3). In two pathways,
a discrepancy was observed between sequence-based reconstruction and literature: (i)
a fully functional TCA cycle was reconstructed (16), whereas the literature indicated this
cycle is partially dysfunctional (10); and (ii) despite reported cysteine auxotrophy (12),
genes encoding the full pathway from sulfate to cysteine are present, although the
genes responsible for the early steps (conversion of sulfate into sulfite via 3=-
phosphoadenylyl sulfate) are annotated as pseudogenes (16). To maintain consistency,
FIG 1 Genome-scale metabolic network of Bordetella pertussis Tohama I (iBP1870). Core metabolic network highlighting newly
discovered active pathways and compounds that have been experimentally verified as possible sole sources of C, N, and/or S. PG,
peptidoglycan; f6p, D-fructose 6-phosphate; g3p, glyceraldehyde 3-phosphate; pyr, pyruvate; lac, L-lactate; ser, L-serine; cys, L-cysteine;
ala, L-alanine; so4, sulfate; mercppyr, mercaptopyruvate; tsul, thiosulfate; accoa, acetyl-coenzyme A; ace, acetate; cit, citrate; a-KG,
-ketoglutarate; succ, succinate; fum, fumarate; mal, malate; oaa, oxaloacetate; nh4, ammonium; pro, L-proline; gln, L-glutamine; glu,
L-glutamate.
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the corresponding reactions were retained in the model but constrained to carry no
flux by default, to account for their reported nonfunctionality (see the supplemental
material).
Energy parameters were determined based on measured metabolic fluxes in refer-
ence fermentations, assuming a partially dysfunctional TCA cycle (no flux allowed from
oxaloacetate to -ketoglutarate [10]). The deduced biomass yield YATP of 3.6 mg of dry
cell weight (mgDCW) per mmolATP is in the range of previously reported values for B.
pertussis (2.7 mgDCW · mmolATP1; see reference 19 and Data Set S4). A value of 9.21
mmolATP · gDCW1 · h1 was calculated for the non-growth-associated maintenance
energy requirement mATP, which is in the range of values reported for E. coli (8.39
mmolATP · gDCW1 · h1; [18]) but higher than previously reported for B. pertussis (0.83
mmolATP · gDCW1 · h1; see reference 19 and Data Set S4). This discrepancy is likely
attributable to the use of different strains and growth conditions (cultivation mode
[batch versus chemostat], medium, pH regulation, and temperature).
To validate the predictive value of the calibrated model, the growth yield of B.
pertussis in 12 chemically defined media was simulated using flux balance analysis (FBA)
with model iBP1870. Two data sets were used: (i) a set of 6 shake-flask cultures in media
with various ratios of glutamate, lactate, and ammonia, published by Thalen et al. (10),
and (ii) a set of 6 pH-controlled batch fermentations in newly formulated media, all
containing L-Glu as a main source of carbon and nitrogen, with various additional N and
C sources (Data Set S5). With both data sets, model predictions were in good agree-
ment with experimentally measured yields, confirming the ability of the parameterized
model iBP1870 to accurately and quantitatively predict biomass yields under various
growth conditions (Fig. 2).
Novel end products of N metabolism in B. pertussis. The reference fermentations
used for model calibration showed a massive apparent nitrogen imbalance, where
ammonia and biomass accumulation only accounted for 37% and 32% of the N
consumed via amino acid uptake, respectively. This left approximately 30% of the N
unaccounted for. Such an imbalance had already been repeatedly observed (12, 13) but
remains unexplained.
The metabolic model was used to suggest additional N sinks: by constraining all
measured input and output fluxes by their measured value, and given the mass balance
constraints, all possible feasible flux values for unknown fluxes were computed by flux
variability analysis (FVA) (20, 21). FVA predicted L-Arg, along with purine/pyrimidine
nucleobases and their nucleoside/nucleotide derivatives, as potential N sinks. Using a
FIG 2 Validation of predicted biomass yields. (A) Validation versus experimental biomass yields in
shake-flask cultures using media with various ratios of glutamate, lactate, and ammonia, as obtained
from Thalen et al. (10). (B) Validation of predicted versus experimental biomass yields in pH-controlled
batch fermentations using newly formulated media (Data Set S5). All simulations were made with a
partially dysfunctional TCA cycle.
Branco dos Santos et al. Applied and Environmental Microbiology
November 2017 Volume 83 Issue 21 e01528-17 aem.asm.org 4
 o
n
 N
ovem
ber 16, 2017 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
liquid chromatography-mass spectrometry (LC-MS)-based approach (Fig. 3A), we were
able to detect 11 additional N-containing end products, seven of which were further
quantified over time in the reference fermentations used for model construction. In
agreement with FVA predictions, arginine, adenine, adenosine, cytidine, deoxycytidine,
deoxyguanosine, and thymidine were detected in increasing concentrations during the
course of the fermentation (Fig. S3). Adenine alone accounted for 5 to 6% of the N
balance. L-Arg represented an additional 3 to 6% (Fig. 3B).
The newly identified N sinks have a high N-to-C ratio (especially purines and
arginine). Their secretion as an alternative to ammonia is therefore an efficient way to
eliminate excess nitrogen while limiting the amount of carbon wasted. Nevertheless,
such biosynthetic products are energy-costly “waste” products, as confirmed by the
analysis of iBP1870, which indicated that the secretion of other compounds, such as
FIG 3 Novel end products of N metabolism in B. pertussis. (A) Schematic description of the procedure used for MS-based identification of metabolic end
products. HMDB, human metabolome database; see the Fig. 1 legend for other abbreviations. (B) Overview of N sinks in reference fermentations highlighting
newly identified sinks are in green.
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alternative amino acids, would be preferable from an energetic perspective. The
observed metabolic behavior therefore suggests a role for these alternative N sinks
beyond mere nitrogen excretion.
Minimal growth requirements of B. pertussis Tohama I. To probe the full meta-
bolic potential of B. pertussis Tohama I, we computed the combinations of minimal
nutrient inputs that would support growth. As this is a combinatorial problem (the
presence of one nutrient may affect the need for another), we developed enumeration
of minimal active fluxes (EMAF) (Fig. 4 and S4), an algorithm that is able to (i) return the
minimum number of active fluxes within a given set of reactions that support some
objective flux, and (ii) enumerate all possible minimal combinations of fluxes (here,
substrate uptake), specifically differentiating between absolutely required fluxes (aux-
otrophies) and sets of interchangeable fluxes (see the supplemental material). EMAF
was implemented in the open-source modeling environment CBMPy (22).
We first applied EMAF to compute possible sulfur sources. B. pertussis is reported to
be auxotrophic for cysteine, i.e., inorganic sulfur sources cannot support growth (11). In
agreement, EMAF predicted no growth with L-Met, oxidized glutathione, sulfite, or
sulfate as sole S sources, and it correctly predicted L-Cys and reduced glutathione as
possible S sources in a minimal medium containing glutamate as the sole source of C
and N. Unexpectedly, the algorithm also returned 5 additional S sources that would
allow growth on the same minimal medium but had never been tested previously or
had been reported to be nonfunctional, with 3 inorganic (sulfur dioxide, thiocyanate,
FIG 4 Enumeration of minimum number of active fluxes (EMAF) algorithm. (A) Schematic overview of EMAF. Based on the
listed inputs, it enumerates all possible minimal combinations of active fluxes that satisfy a given criteria (detailed in
supplemental material). (B) Practical applications of EMAF explored in this study. We minimized all input reactions and used
different constraints to mimic specific conditions. All substrates depicted have been experimentally tested and confirm the
metabolic versatility of B. pertussis.
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and thiosulfate) and 2 organic (mercaptopyruvate and taurine) compounds. When
tested experimentally, growth was confirmed with mercaptopyruvate and with thio-
sulfate (Fig. 5A), one of the most abundant inorganic sulfur species in the environment
(23) and a constituent of human body fluids. According to the reconstituted metabolic
network, thiosulfate is converted to cysteine in two steps: thiosulfate disproportion-
FIG 5 Minimal growth requirements of B. pertussis. (A) Growth of Tohama I with single S sources. Cells were grown in IMP-CDM lacking all S sources and
supplemented with single S sources, as indicated, in 96-well microtiter plates. Biomass yield is expressed as the final OD, from which the final OD of the negative
control (cultures in IMP-CDM with no S source) was subtracted. Each point represents the average of 4 independent repeats; error bars represent the standard
deviation. (B and C) Growth of Tohama I with single amino acids as sole N and C sources (B) or single organic acids as sole C sources (C). Cells were cultivated
in minimal media with no source of N and C, supplemented either with single amino acids (B) or with single organic acids and ammonia (C), in shake flasks.
Growth is expressed as the number of generations from the start of the culture, from which the background number of generations was subtracted (negative
control with no C source). (B) Black lines indicate conditions predicted not to require the TCA cycle, and brown lines indicate conditions predicted to require
a fully functional TCA cycle. Each curve is from one representative experiment from at least 3 independent repeats. Growth was considered positive when
cultures displayed at least one generation over the entire cultivation time. (D) Growth of alternative strains. Cells were cultivated in minimal media with different
C, N, and S sources (as indicated), in 48-well plates. Biomass yield is expressed as the OD after 9 days, after deduction of the OD of cultures of the corresponding
isolates in the same media but without a source of C. Data represent the average of at least 3 independent repeats; error bars represent the standard deviation.
The growth threshold was arbitrarily set at a biomass yield of 0.1, which corresponds to approximately 1.6 generations from the start of cultivation. For all
strains, positive controls in medium IMP-CDM confirmed growth (not shown).
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ation (reaction associated with gene BP0431), yielding sulfite and hydrogen sulfide,
followed by cysteine synthesis from O-acetylserine and hydrogen sulfide (cysteine
synthase B, BP0958). This pathway allows the missing reactions to be bypassed in the
biosynthesis of cysteine from sulfate. This is a significant finding, as it expands the
range of possible S substrates from strictly organic to inorganic and non-cysteine-
containing S sources.
B. pertussis is generally believed to require glutamate or proline exclusively for
growth (11, 24), which is attributed to a partially dysfunctional TCA cycle (10). We used
EMAF to probe the ability of B. pertussis Tohama I to grow on different amino acids as
the sole C or N source in the presence of thiosulfate and oxygen. Without a complete
TCA cycle, indeed, only glutamate and related amino acids (proline and glutamine)
could sustain in silico growth. In contrast, with a complete TCA cycle, all amino acids but
histidine (for which no catabolic pathway was identified) would suffice as the sole C or
N source. Experimentally, the growth of strain Tohama I was observed with four amino
acids that required a functional TCA cycle for in silico growth: aspartate and asparagine
sustained growth to levels only slightly below those of glutamine, while serine and
alanine resulted in modest, yet significant growth (Fig. 5B). Experiments did not match
the in silico predictions for 10 amino acids (tyrosine and cysteine were not tested),
which can likely be explained by regulatory limitations not considered in purely
stoichiometric models (25).
One important consequence of the presence of a fully functional TCA cycle was the
possibility to completely dissociate the N, S, and C sources as inorganic ammonia,
inorganic thiosulfate, and an organic acid as the C source. These predictions challenged
the paradigm that B. pertussis absolutely requires amino acids for growth and that
organic acids can be used only in the presence of an amino acid source (10, 26). We
confirmed that a number of organic acids, including citrate, L-lactate, and to a lower
extent, acetate, pyruvate, fumarate, and succinate, were able to support growth in the
absence of any amino acid (Fig. 5C), although the observed growth rates under such
minimal conditions were very low.
These data provide compelling evidence for the presence of a complete TCA cycle,
as predicted from the genome sequence of strain Tohama I. Altogether, these
simulation-driven experiments indicate that the metabolic requirements of B. pertussis
Tohama I are not only very minimal but also significantly more versatile than previously
alleged. The minimal set of nutrients, apart from niacin (9) includes inorganic phos-
phate (P source), ammonia or amino acids (N source), thiosulfate, mercaptopyruvate, or
cysteine-containing compounds (S source), and a source of C (amino acids or organic
acids). Such nutrients are reasonably accessible not only in the human host but also in
other non-host-associated ecosystems.
Extrapolation to circulating Bordetella strains. Strain Tohama I is a clinical isolate
that was isolated before the vaccination campaigns, and its representativeness of the
B. pertussis species has been questioned (27). We thus verified whether the demon-
strated metabolic versatility of Tohama I would also apply to other strains of the
Bordetella genus (B. pertussis, B. bronchiseptica, and B. parapertussis). Metabolic net-
works were reconstructed for 8 additional strains of B. pertussis, 4 strains of B. bron-
chiseptica, and 2 strains of B. parapertussis (16, 28–30) by curating the output of a newly
developed web-based algorithm pipeline (http://f-a-m-e.org/fijo/) that facilitates the
generation of genome-scale models based on genome sequence (Data Set S8). For each
minimal medium composition that supported the in silico growth of B. pertussis Tohama
I, the corresponding set of active reactions was retrieved from EMAF and compared to
the reaction list of the reconstructed networks.
For all minimal substrate combinations that supported the growth of strain Tohama
I experimentally, the necessary genes were also found in all other B. pertussis strains,
irrespective of their geographical or temporal origin (Fig. S5). In order to validate these
predictions experimentally, we selected 5 strains of B. pertussis, including strain 18323,
the strain most distantly related to Tohama I (30), as well as 4 recent clinical isolates
Branco dos Santos et al. Applied and Environmental Microbiology
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carrying either the ptxP1 (B1834 and B1920) or ptxP3 (B1831 and B1917) allele (29).
These strains were cultivated in selected minimal media in order to validate the use of
thiosulfate as a sulfur source and the functionality of the TCA cycle (Fig. 5D).
The presence of a functional TCA cycle was confirmed in 3 of the 4 recent isolates
(B1917, B1920, and B1834), as demonstrated by their ability to grow with aspartate as
a sole C or N source and an organic S source (cysteine and reduced glutathione). With
this experimental setup, we could not demonstrate a functional TCA cycle in strains
18323 and B1831. Thiosulfate utilization was found to be restricted to strains Tohama
I and 18323, as indicated by the absence of growth of the 4 recent isolates in a medium
composed of glutamate as a sole C or N source and thiosulfate as a sole S source.
Consistent with these results, only strain Tohama I was able to grow with TCA
cycle-dependent C or C or N sources (aspartate, citrate, or L-lactate) when thiosulfate
was the source of S. Intriguingly, whereas Tohama I was able to grow with citrate as a
sole C source and thiosulfate as a source of S (Fig. 5D) (also see Fig. 5C and Table 1 for
a confirmation of this behavior in alternative experimental setups), no growth was
observed when thiosulfate was replaced with an organic source of S (cysteine and
glutathione). Similarly, none of the 3 alternative strains shown to contain a functional
TCA cycle could grow under these conditions.
In conclusion, we were able to demonstrate that some of the newly identified
metabolic features observed in Tohama I extend to other B. pertussis strains (including
recent clinical isolates). However, we cannot conclude that this is a general character-
istic of the species, as only Tohama I appears to combine a functional TCA cycle and the
ability to use thiosulfate. The discrepancy between experimental observations and
genome sequence information can possibly be explained by a differential regulation of
gene expression between strains, a phenomenon recently shown to affect not only
virulence genes but also metabolic genes in B. pertussis (31). Posttranscriptional layers
of regulation might also play a role. The observation that the functionality of the
Tohama I TCA cycle is obscured under certain conditions further supports the role of
regulation in this context. It thus seems that the metabolic flexibility of B. pertussis is a
strain-dependent trait governed by regulation rather than mere gene content.
New medium formulations for vaccine production. The newmetabolic knowledge
gained from our model-based approach is contained within the genome-scale model
TABLE 1 Growth and virulence factor production for B. pertussis strains Tohama I and 18323 cultivated in different chemically defined
mediaa
Medium type
and strain Mediumb pH regulation
Initial
OD650c
Final
OD650
Fermentation
durationd
Avg doubling
time (h)e
PT yield
(mg/liter)f
FHA yield
(mg/liter)g
Minimal media
Tohama I SS 50% (wt/vol) H3PO4 0.138 1.8 63h00 17.2 0.8 0.4 10.5
CIT-NH3 50% (wt/vol) H3PO4 and
1 M K2HPO4
0.007 6.5 159h00 16.1 0.5 27.4
Rich media
Tohama I MSS-CDMf 50% (wt/vol) acetic acid 0.168 8.7 45h40 7.0 15.2 1.3 124.9
IMP-CDM 50% (wt/vol) H3PO4 0.155 8.3 47h00 7.9 29.0 2.6 ND
IMP2-CDM 50% (wt/vol) H3PO4 0.177 8.3 41h15 7.2 36.7 2.2 103.2
LCMSSB 50% (wt/vol) H3PO4 0.104 4.1 33h00 6.2 2.7 1.8 14.1
MSS-CDM 50% (wt/vol) H3PO4 0.159 7.8 39h00 6.7 22.5 3.9 112.9
IMP2-CDM-AA as in
MSS-CDM
50% (wt/vol) H3PO4 0.167 8.7 43h15 7.6 32.3 1.7 ND
18323 MSS-CDM 50% (wt/vol) acetic acid 0.040 8.1 51h00 6.7 4.7 2.2 10.0
IMP2-CDM 50% (wt/vol) H3PO4 0.023 10.1 74h00 8.5 17.3 2.6 34.0
aAll fermentations were performed with a chemical antifoam for foam control.
bMedium compositions provided in Table 3.
cInitial biomass concentration calculated based on measured OD650 of the preculture and inoculum/medium volumes.
dThe total fermentation time is defined as the time at which oxygen consumption decreases (as a consequence of glutamate exhaustion), resulting in a decrease in
stirring speed.
eAverage generation time calculated as the ratio between OD650 at the end of fermentation and OD650 at the start of fermentation, converted to log2, and divided by
the total fermentation time.
fAverage of at least four independent repeats of the PT ELISA  standard deviation.
gAverage of two independent repeats. ND, not determined.
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(Model S1, available at https://github.com/SystemsBioinformatics/pub-data/tree/master/
bordetella-pertussis-model), both from a qualitative (new functional pathways) and
quantitative (energy parameters) point of view. A straightforward application of such
information is the optimization of growth media. We thus tested whether improved
fermentation media could be designed for vaccine production, based on this newly
acquired knowledge.
For pertussis vaccines, whether whole cell or acellular, the fermentation process is
critical, as it is the step where antigens are produced. Yet, current industrial culture
conditions of B. pertussis result in relatively poor yields of the different antigens, more
specifically pertussis toxin (PT) (32). PT production in minimal media, such as the
classical Stainer-Scholte (SS) medium, is low in the absence of additional amino acids
(4). This was confirmed in a 20-liter scale-down model of an industrial fermentation
process with strain Tohama I (Table 1). Based on the discovered metabolic capabilities
of B. pertussis Tohama I, we tested a minimal medium containing only citrate as a C
source and ammonia as an N source (CIT-NH3). Significant growth was observed
(biomass yield over 3-fold higher than with SS medium; Table 1), confirming the
functionality of the TCA cycle of B. pertussis Tohama I under industrial-like conditions.
However, growth was slow and resulted in extremely low antigen production (espe-
cially PT [Table 1]), making such amino acid-free media unsuitable for industrial vaccine
production.
Since minimal media based on alternative substrates did not improve PT production,
we subsequently aimed to rationally improve MSS-CDM, a medium that contains 14
amino acids in addition to glutamate and that already produces acceptable levels of PT
(Table 1). We focused on PT as a proxy for the global antigen production, as PT belongs
to the most tightly regulated class of virulence factors in B. pertussis, and conditions
that result in high PT production also promote high-level expression of all other
virulence factors (33, 34). Model iBP1870 does not contain PT explicitly; yet, assuming
PT and biomass production are coupled, optimization of the basic MSS-CDM process
was performed using FBA, with biomass as the objective. We applied as constraints that
it must: (i) produce the exact same biomass yield as that obtained with the original
basic MSS-CDM; (ii) exclude sulfate as a substrate, as sulfate is one of the most potent
inhibitors of PT production (35); (iii) allow (not force) all components of the basic
MSS-CDM to be taken up at maximally twice the amount actually consumed in the
reference fermentations; and (iv) not restrict end product formation except for sulfate,
sulfite, and sulfur dioxide, compounds known to inhibit PT production (modulators of
the Bvg two-component transduction system, which regulates virulence gene expres-
sion). As an output, a list of optimal balanced ratios between substrates was obtained.
The predicted medium (IMP-CDM) was tested experimentally with strain Tohama I
and found to support a growth yield and rate similar to those of the initial MSS-CDM,
with a 1.9-fold higher production of PT (Table 1). By repeating the FBA-based procedure
and allowing alternative S sources as the substrates, a medium containing thiosulfate
instead of cysteine was designed (IMP2-CDM), which resulted in a 2.4-fold improvement
of PT production compared to that with the reference MSS-CDM process (Table 1). This
represents a 14-fold increase compared to PT production by Tohama I when grown
according to the best batch process published to date (medium LCMSSB [36]; Table 1).
Filamentous hemagglutinin (FHA) production remained unaffected in IMP2-CDM com-
pared to the reference MSS-CDM conditions (Table 1). We found a similar relative
improvement of PT yield with the distantly related strain 18323 (Table 1).
Model-driven process and medium modifications accounted for 91% of the total PT
improvement of Tohama I grown in IMP2-CDM, as estimated from fermentations in
which specific subsets of modifications were not implemented (Table 2). The highest
contributor to PT yield improvement was the replacement of cysteine with thiosulfate
(36%), a direct output of FBA when imposing the constraint that no sulfate can be
produced and that S sources other than cysteine are allowed. Thiosulfate was found to
be as potent as sulfate as a modulator of PT production (data not shown). However,
thiosulfate serves here as an S source and is therefore consumed during growth in the
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optimized medium, which gradually relieves BvgAS-mediated repression of PT produc-
tion; conversely, in classical media using cysteine as a source of S, sulfate progressively
accumulates as a result of cysteine catabolism, resulting in a steadily decreasing PT
production during the course of the fermentation process (36). Equally important (34%
of all improvements) was the replacement of acetic acid with phosphoric acid for
pH regulation, which results in lower acetate accumulation (an inhibitor of growth
and macromolecule synthesis [37]) and higher phosphate supply. This process
modification was introduced after the detailed metabolic characterization of the
reference fermentations, in which acetate accumulated up to 180 mM but phos-
phate was limiting (Fig. S1).
The third major contributor to PT improvement was the balancing of amino acid
concentrations, which accounted for 21% of the PT yield increase in the improved
medium (Table 2). The reason why amino acid concentrations have such a significant
effect on PT production is unclear. Although it cannot be excluded that this effect is the
consequence of changing the concentration of one (or a few) specific amino acid(s)
with regulatory function, it may also reflect a globally more balanced, and hence,
energetically efficient, cometabolism of substrates. This is supported by the higher
ammonia production under improved cultivation conditions, representing 52% of the
N end products (only 37% in the basic MSS-CDM process). Such a precise balancing of
substrate concentrations can only be achieved by taking into account the complex
metabolic interconnections between pathways at the whole-cell level, combined with
a fine knowledge of biomass composition. In this context, genome-scale mechanistic
models provide a clear benefit over traditional optimization techniques based on
empirical correlations between parameters, as the traditional techniques are virtually
unable to provide balanced media, and they require a very high number of cultures.
DISCUSSION
In this work, we reconstructed a comprehensive genome-scale metabolic network
for Bordetella pertussis. Model iBP1870 is much more detailed than the only B. pertussis
model in the literature, which was limited to reactions involving amino acids and
by-products considered to be main contributors to the carbon and nitrogen balance (4).
iBP1870 is the result of multiple cycles of manual curation, in which the network was
tuned to match genome sequence information of strain Tohama I, literature data, and
newly generated experimental evidence. A particular effort was invested in defining the
macromolecular composition of the cells; this resulted in insights into previously
TABLE 2 Quantitative contribution of medium and process changes to increased PT yield
with IMP2-CDM-based process
Change description
Relative PT
yielda
Relative contribution to overall
PT yield improvement (%)
Replacement of cysteine with thiosulfate
as S source
1.51b 34
pH control with phosphoric instead of
acetic acid
1.48c 36
Balancing of amino acid concn 1.29d 21
Totale 2.28 91
Unexplained/other changesf 1.13 9
aCompared to the reference process using medium MSS-CDM and acetic acid for pH regulation (Table 1).
bCalculated as the difference between the relative PT yield with IMP2-CDM (thiosulfate) and IMP-CDM
(cysteine) media, compared to MSS-CDM medium with acetic acid for pH regulation (Table 1).
cRelative PT yield of fermentation using phosphoric acid or acetic acid for pH regulation with MSS-CDM
medium (Table 1).
dCalculated as the difference between the relative PT yield with IMP2-CDM (balanced amino acid
concentrations) and IMP2-CDM-AA as in MSS-CDM (original amino acid concentrations) media, compared to
MSS-CDM medium with acetic acid for pH regulation (Table 1).
eTotal improvement that can be explained with the above-listed medium and process changes.
fThe unexplained part of PT yield improvement can possibly be attributed to other medium changes in
IMP2-CDM versus MSS-CDM (buffer, additional minerals, and/or additional vitamins), although each of these,
when tested separately, did not show a significant effect on PT yield (data not shown).
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undescribed pathways or metabolites. iBP1870 includes detailed biosynthetic pathways
for B. pertussis-specific metabolites, among which are lipooligosaccharides (LOS) and
the siderophore alcaligin, two key virulence factors of this pathogen (6); it also includes
more general pathways for polyphosphate and amino acid metabolism, for which 84
reactions were added (Data Set S3). The resulting model is thus a knowledge base that
will be a valuable resource for future metabolic reconstructions of related strains and
organisms.
In the present study, we illustrated the use of the B. pertussis model in contexts
relevant to the overall physiology and ecology of this organism, as well as to biotech-
nological applications.
First, we explored the metabolic landscape in terms of nutrient requirements and
identified a greatly expanded repertoire of growth modes for B. pertussis Tohama I.
Importantly, a significant proportion of these novel growth regimes require a key
pathway (the TCA cycle) whose functionality in B. pertussis was subject to debate (4, 5,
10). Although two recent studies reported a similar conclusion in strains Tohama I (5)
and 10536 (4), their evidences were based on the observation that metabolic flux
distributions were better accounted for from a quantitative perspective, when assum-
ing this pathway was functional. Nevertheless, growth could also be explained quali-
tatively without a TCA cycle, under their conditions. Izac et al. also demonstrated that
the necessary genes were transcribed and that the corresponding enzymatic activities
were detectable in in vitro assays (5). Here, by demonstrating growth on a number of
organic acids as sole C sources, we provide direct in vivo evidence that the TCA cycle
of strain Tohama I is fully functional: with organic acids, such as citrate, as the sole C
source, growth cannot be explained without a TCA cycle. The functionality of the TCA
cycle, however, appears to be under the control of regulatory networks, making it a
strain-dependent characteristic: it could only be demonstrated experimentally with 3 of
the 5 alternative strains tested, despite the presence of the necessary genes in all
genomes.
Cysteine auxotrophy, as another major paradigm of pertussis metabolism (11, 16),
was also contradicted by model simulations and experimental evidence: B. pertussis
Tohama I is able to use a significantly wider range of S sources than generally accepted
(including S-containing organic acids and inorganic thiosulfate), which demonstrates
the functionality of new pathways for the de novo synthesis of cysteine. This metabolic
trait was only confirmed in one additional strain (18323), whereas 4 recent clinical
isolates failed to grow experimentally with thiosulfate as a sole S source, despite the
presence of the genes required for thiosulfate utilization.
Altogether, our findings thus reveal three key features of B. pertussis metabolism.
First, it can be versatile, as characterized by the large variety of substrate combinations
that can be used for growth. Second, it can be minimal, in the sense that growth is
possible in minimal, nearly mineral media (only the C source must be organic). Third,
the above-mentioned characteristics seem, however, to rely on regulatory (nonmeta-
bolic) strain-specific features, resulting in strain-to-strain variability. This likely explains
discrepancies between different reports, such as the debate about the presence of a
functional TCA cycle (4, 5, 10).
Although the demonstrated metabolic versatility of B. pertussis appears to vary
between strains (Tohama I being the only case where both the TCA cycle and the
thiosulfate utilization pathways are functional), our results indicate that the general
acceptation that B. pertussis is fastidious might be too restrictive. Even if regulatory
constraints or mutations make certain functions inactive in other strains, the presence
of the necessary structural genes is conserved, providing potential for evolution or for
expression under yet-unidentified conditions. Metabolic flexibility could participate in
the survival of B. pertussis in the host, but also in external environments, although other
factors, such as the known susceptibility of B. pertussis to fatty acids (38) or to abiotic
factors (temperature and humidity), probably also play a key role in this context.
As a second application example, we used the B. pertussis metabolic model as a
guide to identify novel end products of nitrogen metabolism. We demonstrated the
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production of significant amounts of purines, purine nucleosides, and arginine as N
sinks (Fig. 3B). Although it cannot be excluded that this observation is the consequence
of artificial growth conditions that differ from the natural environment of B. pertussis,
such an energetically unfavorable metabolic pattern might also reflect a biological role
for these compounds beyond N excretion. To date, the study of interactions between
B. pertussis and its human host have concentrated mostly on protein-based toxins and
adhesins (for example, see reference 6) despite the role of metabolic interactions in this
context (3). Purine nucleosides are well-known modulators of innate immunity, for
example, by decreasing the synthesis of the antimicrobial nitric oxide (NO) through a
diversity of mechanisms (39). Accordingly, adenosine production and a functional
purine biosynthetic pathway have been identified as key virulence factors in several
pathogens (40–44). Arginine production by B. pertussis could further inhibit NO pro-
duction by favoring the accumulation of asymmetric dimethyl-arginine, an endogenous
inhibitor of NO synthases (45, 46). The roles of NO and arginine in respiratory diseases,
such as asthma or cystic fibrosis, which share several symptoms with whooping cough,
are well established (45, 46). Therefore, we speculate that the combined production of
arginine and purine nucleosides contributes to the virulence of B. pertussis by subvert-
ing the host innate immunity: arginine and purine production might thus constitute
alternative targets against B. pertussis infection.
Finally, we also demonstrated the use of the metabolic model for rational medium
and bioprocess design in the context of industrial pertussis vaccine production. Using
an approach based on FBA and the metabolic knowledge acquired during model
construction, a medium was designed that increased the production of PT (the limiting
antigen in acellular pertussis vaccine manufacturing [32]) by 2.4-fold. Alternative ap-
proaches for increasing antigen yields in B. pertussis usually involve genetic engineering
(32, 47), with significant regulatory implications for drug approval. The improved
medium and process conditions developed in this study are readily applicable to
current vaccine strains, such as Tohama I, but also apply to more distantly related
strains, such as 18323 (Table 1). They could also be used in combination with genetic
engineering to further increase yields. From a drug approval perspective, the proposed
modifications are based on a mechanistic understanding of metabolism and regulation
of virulence factors in B. pertussis, providing a sound scientific rationale for process
change. Such a model-guided rational process improvement strategy is thus perfectly
aligned with quality-by-design principles.
Concluding remarks. The approach taken here to probe the full metabolic poten-
tial of an organism is general and can be applied to any sequenced organism for which
a minimum amount of experimental data are accessible or can be generated (Fig. 6).
Here, we used flux data from only two fermentations to adequately calibrate our model.
We show how subsequent model-guided experimentation can provide progress in
metabolic understanding of the physiology of a poorly characterized organism. In this
way, we redefined the physiology and metabolic potential of B. pertussis: it is much
more versatile than previously reported, although this appears to depend on regulatory
strain-specific determinants. This study thus highlights the potential, but also limita-
tions, of models solely based on metabolic gene content. Deciphering and taking into
account the mechanisms responsible for the regulation of metabolic capabilities there-
fore appear to be crucial for a comprehensive understanding of the lifestyle of B.
pertussis and the epidemiology of whooping cough.
MATERIALS AND METHODS
Reference fermentations. Two batch fermentations of B. pertussis Tohama I (fermentations A and B)
were performed in modified Stained-Scholte medium (MSS-CDM) (Table 3). The preculture consisted of
3 serial shake-flask cultures in MSS-CDM that were incubated at 35°C under constant orbital agitation
(150 rpm) for approximately 24 h and harvested in exponential phase. The third preculture (1.5 liters;
optical density at 650 nm [OD650] between 1.5 and 1.6) was used to inoculate a 20-liter fermentation
vessel (Biolafitte) containing 10 liters of MSS-CDM. The fermenter was operated in batch mode at
constant temperature (35°C) and head pressure (40,000 Pa). The culture was sparged with air at a
constant rate of 20 liters/min. A mechanical foam breaker was used to control foaming. pH was regulated
at 7.2 by automatic addition of 50% (wt/vol) acetic acid. The level of dissolved oxygen was regulated at
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25% of its initial level by modulating the stirring speed. Sampling was performed at the start of
fermentation and every 2 h between 18 h and the end of fermentation (abrupt decrease in oxygen
demand). Supernatants and cells were separated by centrifugation (15,000  g, 15 min, 4°C) and stored
at 20°C. Biomass concentration was monitored as the OD650 and dry cell weight (DCW).
PT and FHA quantification. PT and FHA concentrations were determined by enzyme-linked
immunosorbent assay (ELISA) in the culture supernatants, as previously described (48).
Determination of exometabolite fluxes in reference fermentations. In addition to biomass and
PT, a total of 37 metabolites were assayed (Data Set S1). The conversion of exometabolite concentrations
to net fluxes is described in details in Data Set S1. Briefly, exometabolite concentrations were converted
to absolute amounts (millimoles for metabolites and grams [dry cell weight] [gDCW] for biomass) and
corrected for water evaporation, acetic acid addition, and sampling. For each metabolite (including
biomass), the net production/consumption was calculated at every time point by subtracting the amount
initially present from the amount at the time point considered (symbols in Fig. S1). The time courses of
net production/consumption of each metabolite were then spline-fitted using the method of Klasson
(49), with a smoothness factor of 3 (solid and dotted lines in Fig. S1). Phases of constant metabolism were
determined from the spline functions (vertical solid lines in Fig. S1, and Data Set S1).
Determination of biomass composition. The macromolecular composition of cells was determined
based on three sources: (i) experimental measurements at different growth stages on cells issued from
the two batch reference fermentations (DNA content, RNA content, protein content, and amino acid
composition, inorganic phosphate, and polyphosphate), (ii) literature data, and (iii) theoretical calcula-
tions (Data Set S2). Growth was modeled as a sink of biomass components in a proportion that matches
biomass composition (Fig. S2).
Model construction. The metabolic network of B. pertussis Tohama I was reconstructed in three
phases: (i) semiautomatic reconstruction based on model iAF1260 of E. coli MG1655 (18) using
AUTOGRAPH (50), (ii) the addition of new reactions to explain experimentally observed metabolic
behaviors in reference fermentations, and (iii) final manual curation and incorporation of default
constraints to account for reported physiological observations. Model construction is described in details
in the supplemental material and Data Set S3. The curated model iBP1870 is provided in SBML format
at our GitHub repository: https://github.com/SystemsBioinformatics/pub-data/tree/master/bordetella
-pertussis-model.
FIG 6 Model-based strategy to improve medium composition and generate new physiological knowledge. Arrows represent information
flow. HT assays, high-throughput growth assays.
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Determination of energy parameters. Maintenance and growth-associated ATP consumption were
determined using flux balance analysis (FBA) on model iBP1870, as previously described (51), using
extracellular flux constraints derived from the two reference batch fermentations (each subdivided into
5 phases of constant metabolism). The mathematical framework and assumptions underlying the
calculations are described in details in the supplemental material and Data Set S4.
Model validation. FBA was used in combination with model iBP1870 to compute the maximum
possible biomass production under constraints reflecting substrate availability in different media (Data
Set S5). For every simulation, maintenance energy consumption was calculated based on measured
growth parameters (initial biomass, cultivation time, and specific growth rate) and was introduced in the
simulations as the lower bound of the R_ATPM ATP hydrolysis reaction (Data Set S5). Additional
constraints were set to mimic a partially nonfunctional TCA cycle. The simulation results were compared
to experimental growth yields, as derived from the literature (10) (data of Fig. 2A) or as generated by
cultivating strain Tohama I in newly formulated media (Data Set S5) under the same conditions as in the
reference fermentations (Fig. 2B).
LC-MS analyses of reference fermentations. For the qualitative identification of N sinks, superna-
tant samples from the endpoint of the two reference fermentations were mixed (1:1 ratio), diluted (1.7-,
3.3-, 5.5-, or 10-fold), and analyzed by LC-MS, as described in the details in Data Set S6. We found 108
m/z values (88 in positive mode, 20 in negative mode) whose peak areas varied proportionally between
at least two consecutive dilutions, corresponding to 13,056 possible matches in the human metabolome
database (52) (tolerance set to less than 0.1 Da). Of these, 65 compounds were also found in the
metabolic network of B. pertussis, 32 of which were analyzed by LC-tandem MS (LC-MS/MS) to confirm
TABLE 3 Fermentation medium compositiona
Compound
Concn (mg/liter)
MSS-CDM CIT-NH3 IMP-CDM IMP2-CDM
IMP2-CDM-AA as
in MSS-CDM
L-Proline 1,040 0 882 882 1,040
Na-L-glutamate 20,000 0 18,677 18,677 18,677
L-Cysteine HCl 40 0 4 0 0
Na2S2O3·5H2O 0 5.65 0 2.83 2.83
NaCl 2,500 0 73 73 73
KH2PO4 500 500 500 500 500
KCl 200 200 200 200 200
MgCl2·6H2O 100 1,000 1,000 1,000 1,000
CaCl2·2H2O 20 20 20 20 20
FeSO4·7H2O 10 0 0 0 0
Fe(III)-citrate·3H2O 0 20 20 20 20
Tris 6,100 0 0 0 0
CuCl2·2H2O 0 1.28 1.28 1.28 1.28
CoCl2·6H2O 0 0.42 0.42 0.42 0.42
ZnCl2 0 10 10 10 10
MOPS 0 2,500 2,500 2,500 2,500
Ascorbic acid 400 623 623 623 623
Reduced glutathione 150 233 233 233 233
Niacin 4 6 6 6 6
Dimethyl--cyclodextrin 1,000 1,000 1,000 1,000 1,000
Na acetate 0 0 409 409 409
L-Alanine 312 0 304 304 312
L-Aspartic acid 436 0 524 524 436
L-Glutamic acid 1,600 0 3,475 3,475 3,475
L-Histidine 188 0 32 32 188
L-Glycine 163 0 149 149 163
L-Isoleucine 288 0 244 244 288
L-Leucine 484 0 438 438 484
L-Lysine HCl 600 0 393 393 600
L-Methionine 156 0 116 116 156
L-Phenylalanine 250 0 234 234 250
L-Serine 230 0 187 187 230
L-Tyrosine 67 0 34 34 67
L-Valine 456 0 399 399 456
Thiamine-HCl 0 10 10 10 10
Biotin 0 0.2 0.2 0.2 0.2
Riboflavin 0 0.3 0.3 0.3 0.3
Calcium pantothenate 0 4 4 4 4
Citric acid monohydrate 0 26,268 0 0 0
Ammonium hydroxide 25% 0 5,066 0 0 0
apH adjustment was made to pH 7.4 (25°C) with 5 M NaOH and 6 M HCl.
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their presence in the fermentation supernatants by comparison with commercial standards: a compound
was considered present in a sample provided (i) the retention time (RT) did not deviate by more than 0.5
min compared to the RT of the standard (pure compound) and (ii) at least 2 of the characteristic MS/MS
transitions (as determined with the standards) were detectable. Among the 12 metabolites confirmed to
be present at the end of the reference fermentations (including 11 N-containing end products), six
(adenine, adenosine, cytidine, thymidine, deoxyguanosine, and deoxycytidine) were quantified at differ-
ent time points of the fermentations, by standard addition using LC-MS/MS (Data Set S6). Adenine was
also quantified with an enzyme-based assay (53). L-Arginine was quantified with an enzymatic kit
(K-Large; Megazyme, Ireland).
Prediction of minimal growth requirements. For strain Tohama I, the EMAF algorithm (supple-
mental material) was used in combination with model iBP1870 and appropriate constraint sets (Data Set
S7) to screen single S, C or N (amino acids), and C sources (organic acids) that can support growth of B.
pertussis Tohama I in silico with or without a functional TCA cycle.
For the 14 alternative Bordetella strains (30), the metabolic networks were reconstructed with FiJo
(http://f-a-m-e.org/fijo) using model iBP1870 as the template, and manually curated (Data Set S8). From
the metabolic flux distribution for each minimal medium composition that did support in silico growth
of B. pertussis Tohama I (Data Set S7), the set of active reactions was extracted. Growth was determined
to be feasible if all required reactions for in silico growth of B. pertussis Tohama I were also present in the
reconstructed network; conversely, if only one required reaction was not present, growth was assumed
to be not feasible.
Experimental validation of minimal growth requirements. Experimental validation of S sources
with Tohama I was done with IMP-CDM medium (Table 3) lacking L-cysteine, L-methionine, and
glutathione and supplemented with sodium thiosulfate, reduced glutathione, L-cysteine–HCl, or mer-
captopyruvate at different concentrations, or with water as a negative control. Growth assays were
performed in 96-well plates (Greiner 655090) containing 180 l of medium and 20 l of inoculum. The
inoculum was prepared by growing cells in MSS-CDM in a shake flask to an OD650 between 1 and 2,
collecting cells by centrifugation (5,000  g, 15 min, 25°C), washing the cell pellet twice with 1 volume
of 0.9% (wt/vol) NaCl, and resuspending cells in 0.9% (wt/vol) NaCl at a theoretical OD650 of 0.5. After
inoculation, the 96-well plate was incubated for 7 days at 35°C and constant double orbital agitation in
a Synergy H1 microplate reader (BioTek). Growth was monitored every 10 min as the OD650.
For all other validations, the inoculum was prepared as described above (except for resuspension of
the washed cells [see below]), and growth assays were performed with a basal medium containing no
source of C, N, or S (0.5 g/liter KH2PO4, 2.5 g/liter morpholinepropanesulfonic acid [MOPS], 0.2 g/liter KCl,
6 mg/liter niacin, 1 g/liter dimethyl--cyclodextrin, mineral salts [1 g/liter MgCl2·6H2O, 100 mg/liter
CaCl2·2H2O, 20 mg/liter Fe(III)-citrate·H2O, 1.28 mg/liter CuCl2·2H2O, 0.42 mg/liter CoCl2·6H2O, 10 mg/
liter ZnCl2]) and vitamins (0.2 mg/liter biotin, 0.3 mg/liter riboflavin, 10 mg/liter thiamine-HCl, 4 mg/liter
calcium pantothenate), to which sources of C, N, and S were added as required. Media were adjusted to
pH 7.4 (25°C) by addition of 5 M NaOH or 6 M HCl; the concentrations of Na and Cl were adjusted to
at least 110 mM and 30 mM, respectively, with NaCl.
For the validation of amino acids as sole C or N sources and organic acids as sole C sources with
Tohama I, each medium contained thiosulfate 0.25 mM (S source) and either a single amino acid as the
sole C or N source (125 mM, except L-Asp (30 mM) and L-Trp (40 mM) or a single organic acid (100 mM
acetate, pyruvate, citrate, L-lactate, succinate, or fumarate) as the sole C source, together with NH4Cl (25
mM) as the sole N source. As a negative control, a medium containing ammonia but no C source was
used. Growth assays were performed in 250-ml shake flasks containing 30 ml of medium and inoculated
with 1 ml of a washed cell suspension (OD650, 1.2) of exponentially growing B. pertussis Tohama I. After
inoculation, cultures were incubated for 9 days at 35°C under constant orbital agitation (150 rpm).
Growth was monitored offline as the OD650.
For validations with alternative strains (B1831, B1834, B1917, B1920, and 18323, as well as Tohama
I as a control), the following C, N, and S sources were added. The S source was either sodium thiosulfate
(62 mg/liter) or a mixture of L-cysteine (40 mg/liter), reduced glutathione (233 mg/liter), and ascorbic acid
(623 mg/liter). For organic acids as C sources, 1.337 g/liter NH4Cl was added as an N source, together with
21.014 g/liter citric acid monohydrate or 21.005 ml/liter of a 40% L-lactic acid solution. For amino acids
as C or N sources, L-aspartate (4 g/liter) or a mixture of sodium L-glutamate monohydrate (21.79 g/liter)
and L-glutamic acid (1.579 g/liter) was used. As negative controls, strains were grown in media containing
the same S source as the test cultures and ammonia as an N source but no C source. As positive controls,
the 6 strains were grown in IMP-CDM. Growth assays were performed in FlowerPlate 48-well microtiter
plates (m2p labs), with each well containing 800 l of culture (720 l of medium and 80 l of inoculum,
consisting of a washed cell suspension [OD650, 0.5] of exponentially growing cells). After inoculation,
plates were covered with a Breathe-Easy membrane (Sigma) and pierced with 3 holes per well, and
incubation was performed in a BioLector microbioreactor (m2p labs) at 35°C under constant agitation
(800 rpm). After 9 days, the OD650 was measured offline.
Model-based design of optimized media. Optimization of the basic MSS-CDM was performed
using FBA, with constraints as indicated in Results (“New medium formulations for vaccine production”).
FBA outputs were converted into medium formulations (IMP-CDM and IMP2-CDM) based on an
L-glutamate concentration of 120 mM. Additional modifications of medium composition (buffer, vita-
mins, and inorganic ions; not deduced from FBA) were as follows (Table 1): niacin, reduced glutathione,
and ascorbic concentrations increased 1.5-fold; four additional vitamins (riboflavin, thiamine, pantothe-
nate, and biotin) were added; three additional inorganic ions (Cu2, Co2, and Zn2) were added; Mg2
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concentration increased 10-fold; iron was provided as Fe(III)-citrate instead of FeSO4; and Tris buffer was
replaced with MOPS.
Additional fermentations for evaluation of optimized media. Optimized media were tested in
20-liter scale fermentations performed under the same conditions as the reference fermentations, except
for (i) medium composition (Table 3), (ii) strain (Table 1), (iii) a foam control (mechanical foam breaker
replaced with a chemical antifoam, as a 2-fold dilution of 30% simethicone [Dow Corning] in water), and
(iv) pH regulation (Table 1). For fermentations in SS medium, the formulation described in Bogdan et al.
(36) was used. For fermentations with LCMSSB, the conditions of Bogdan et al. (36) were used, which
differ from the conditions of other fermentations in the following aspects: (i) the third preculture was
performed in LCMSSB medium (supplemented with 1 g/liter dimethyl--cyclodextrin), (ii) the
20-liter-scale fermentation was performed in 11 liters of LCMSSB medium inoculated with 1 liter of
a preculture (OD650, 1.25), (iii) when the culture reached an OD650 of 3, amino acid supplements (see
composition in Bogdan et al. [36]) were added to the fermentation, together with a supplement of
FeSO4 and glutamate, as described in Bogdan et al. (36), (iv) foaming was controlled by automatic
addition of simethicone (30% emulsion [Dow Corning Q7-2587] diluted 2-fold in water), which is
essentially similar in composition to Antifoam C (Sigma) used by Bogdan et al. (36), (v) the
temperature was 36.5°C, (vi) a constant aeration rate of 4.0 liters · min1 was used, and (vii) the level
of dissolved oxygen was regulated at 40%.
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